Publication:
Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves

dc.contributor.authorCorum O., Yildiz R., Ider M., Altan F., Ok M., Uney K.
dc.contributor.authorCorum, O, Yildiz, R, Ider, M, Altan, F, Ok, M, Uney, K
dc.date.accessioned2023-05-09T18:33:59Z
dc.date.available2023-05-09T18:33:59Z
dc.date.issued2019-11-01
dc.date.issued2019.01.01
dc.description.abstractThe aim of this study was to evaluate the pharmacokinetics and bioavailability of cefquinome (CFQ) and ceftriaxone (CTX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. Using a parallel design, 24 premature calves were randomly divided into the two antibiotic groups. Each of the six animals in the first group received CFQ (2 mg/kg) through IV or IM administration. The second group received CTX (20 mg/kg) via the same administration route. Plasma concentrations of the drugs were analyzed by high-performance liquid chromatography and noncompartmental methods. Mean pharmacokinetic parameters of CFQ and CTX following IV administration were as follows: elimination half-life (t1/2λz) 1.85 and 3.31 hr, area under the plasma concentration–time curve (AUC0–∞) 15.74 and 174 hr * μg/ml, volume of distribution at steady-state 0.37 and 0.45 L/kg, and total body clearance 0.13 and 0.12 L hr−1 kg−1, respectively. Mean pharmacokinetic parameters of CFQ and CTX after IM injection were as follows: peak concentration 4.56 and 25.04 μg/ml, time to reach peak concentration 1 and 1.5 hr, t1/2λz 4.74 and 3.62 hr, and AUC0–∞ 22.75 and 147 hr * μg/ml, respectively. The bioavailability of CFQ and CTX after IM injection was 141% and 79%, respectively. IM administration of CFQ (2 mg/kg) and CTX (20 mg/kg) can be recommended at 12-hr interval for treating infections caused by susceptible bacteria, with minimum inhibitory concentration values of ≤0.5 and ≤4 μg/ml, respectively, in premature calves. However, further research is indicated to assess the pharmacokinetic parameters following multiple doses of the drug in premature calves.
dc.identifier.doi10.1111/jvp.12789
dc.identifier.eissn1365-2885
dc.identifier.endpage639
dc.identifier.issn0140-7783
dc.identifier.scopus2-s2.0-85067614931
dc.identifier.startpage632
dc.identifier.urihttps://hdl.handle.net/20.500.12597/13429
dc.identifier.volume42
dc.identifier.wosWOS:000501034000008
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.relation.ispartofJOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
dc.rightsfalse
dc.subjectbioavailability | cefquinome | ceftriaxone | pharmacokinetics | premature calves
dc.titlePharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves
dc.titlePharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves
dc.typeArticle
dspace.entity.typePublication
oaire.citation.issue6
oaire.citation.volume42
relation.isScopusOfPublication792c8c5d-0721-4194-a679-ff6a70b68810
relation.isScopusOfPublication.latestForDiscovery792c8c5d-0721-4194-a679-ff6a70b68810
relation.isWosOfPublication128ec7da-87c8-4996-9ff1-72790a915be6
relation.isWosOfPublication.latestForDiscovery128ec7da-87c8-4996-9ff1-72790a915be6

Files

Collections